BeiGene Ltd Profile

<div class='circular--portrait' style='background:#FCD202;color: white;font-size:3em;padding-top: 40px;;'>BGN</div>


0 / 100

Odds of Distress

Analyze Filter   Earning Report: February 26, 2020
Equity ratings for BeiGene Ltd are calculated based on Macroaxis scoring framework. The performance scores are derived for the period starting November 24, 2019 and ending today February 22, 2020. Click here to learn more.

BeiGene Ltd Profile

Upcoming quarterly earning report is expected on February 26, 2020. BeiGene, Ltd., a commercial-stage biotechnology company, develops and commercializes molecularly-targeted and immuno-oncology drugs for the treatment of cancer in the Peoples Republic of China, the United States, and internationally. BeiGene, Ltd. was founded in 2010 and is headquartered in Beijing, the Peoples Republic of China. BeiGene Ltd operates under Biotechnology classification in USA and is traded on BATS Exchange. It employs 3000 people. more on BeiGene Ltd
BeiGene Ltd Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
BeiGene Ltd SEC Filings
BeiGene Ltd SEC Filings
Security & Exchange Commission EDGAR ReportsView All
Legal NameBeiGene Ltd
ChairmanJohn OylerView All
Thematic Classifications
Active investing themes BeiGene Ltd currently participates. An investing theme is an unweighted collection of funds, stocks, ETFs or cryptocurrencies
    Cancer Fighters
Average Analyst Recommendation
Current trade recommendation based on an ongoing consensus estimate among financial analysis covering BeiGene Ltd
Piotroski F Score
Academic score to determine the current strength of BeiGene Ltd financial position
Macroaxis Advice
Macroaxis buy hold or sell recommendation provided in the context of your current investment horizon and risk tolerance.
Horizon: 30 days (very short)Advice
Financial Strength
BeiGene Ltd ability to generate sufficient cash flow to pay bills, repay debt, and make consistent year-to-year profit
Total Debt
Debt Current
Debt Non Current
Debt to Equity Ratio
Return on Average Assets
Return on Average Equity
Return on Invested Capital
Return on Sales
Earnings per Basic Share
Earnings per Diluted Share
Price to Earnings Ratio
Earnings before Tax
Few selected profitability drivers of BeiGene Ltd representing accounts that assess its ability to generate profits relative to its revenue, operating costs, and shareholders' equity
Consolidated Income
Net Income
Net Income Common Stock
Operating Income
Income Tax Expense
Gross Margin
Profit Margin
BeiGene Ltd (BGNE) is traded on BATS Exchange in USA. It is located in No.30 Science Park Road and employs 3,000 people. BeiGene Ltd is listed under Pharmaceutical Products category by Fama And French industry classification. The company currently falls under 'Large-Cap' category with current market capitalization of 13.21 B. BeiGene Ltd conducts business under Healthcare sector and is part of Biotechnology industry. The entity has 77.17 M outstanding shares of which 2.83 M shares are currently shorted by private and institutional investors with about 10.25 trading days to cover. BeiGene currently holds about 1.23 B in cash with (676.98 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 20.32.
Check BeiGene Ltd Probability Of Bankruptcy

Ownership Allocation (%)

BeiGene Ltd Target Price Odds Analysis

Odds Below 173.19HorizonTargetOdds Above 173.19
47.61%30 days 173.19 52.23%
Based on normal probability distribution, the odds of BeiGene Ltd to move above current price in 30 days from now is about 52.23 (This BeiGene Ltd probability density function shows the probability of BeiGene Ltd Stock to fall within a particular range of prices over 30 days) .

BeiGene Ltd Top Holders

BeiGene Ltd Major Institutional Holders

InstituionSecurity TypeTotal SharesValue
Baker Bros Advisors LpCommon Shares11.8 MB
Hillhouse Capital Advisors LtdCommon Shares5.5 M907.1 M
View BeiGene Ltd Diagnostics

BeiGene Ltd Income Statement Over Time

Consolidated Income    Earning Before Interest and Taxes EBIT    Net Income    

BeiGene Ltd Against Markets

Did you try this?

Run Portfolio Holdings Now


Portfolio Holdings

Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
All  Next Launch Module

BeiGene Ltd Upcoming and Recent Events

BeiGene Ltd Company Earnings Announcements Dates

Upcoming Quarterly Earning ReportFebruary 26, 2020
Next Earnings ReportMay 14, 2020
Next Fiscal Quarter EndDecember 31, 2019
Next Fiscal Year EndFebruary 26, 2020
Last Quarter Report DateSeptember 30, 2019
Last Earning Anouncement DateDecember 31, 2018

BeiGene Ltd Corporate Filings

BeiGene Ltd SEC Reporting

Unclassified Corporate Event
Financial Statements and Exhibits. Other Events
Submission of Matters to a Vote of Security Holders
Other Events

BeiGene Ltd Corporate Directors

Continue to Trending Equities. Please also try Transaction History module to view history of all your transactions and understand their impact on performance.
Company logos by clearbit